Neutropenia News and Research

RSS

Neutropenia is a hematological disorder characterized by an abnormally low number of neutrophils, the most important type of white blood cell, in the blood.

New drug combination doubles effectiveness in shrinking enlarged spleens in myelofibrosis patients

Combining the JAK inhibitor ruxolitinib with the BCL-xL inhibitor navitoclax was twice as effective in reducing enlarged spleens – a major indicator of clinical improvement – compared with standard-of-care ruxolitinib monotherapy for adult patients with intermediate or high-risk myelofibrosis, a rare bone marrow cancer, according to results of the Phase III TRANSFORM-1 trial reported by researchers from The University of Texas MD Anderson Cancer Center.

11 Dec 2023

MHRA grants conditional marketing authorization for AbbVie's Tepkinly to treat aggressive blood cancer

AbbVie today announced that the UK Medicines and Healthcare products Regulatory Agency has granted conditional Marketing Authorisation for Tepkinly® (epcoritamab) as a monotherapy for the treatment of adults with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), after two or more systemic therapies.

28 Oct 2023

Resistant potato starch usage found to be feasible and safe for hematopoietic stem cell transplantation patients

The use of resistant potato starch (RPS), to modify gut microbial metabolism.

24 Oct 2023

Stem cell transplant offers hope for patients with multiple sclerosis

Stem cells harvested from a person's own bone marrow or blood, can safely slow progression of the most common form of the autoimmune disease, multiple sclerosis, or MS as it's usually known, finds research published online in the Journal of Neurology Neurosurgery & Psychiatry.

26 Sep 2023

Stem cell transplant offers hope for MS patients, study finds

Autologous hematopoietic stem cell transplantation, or aHSCT for short, is usually used to treat blood cancers, and involves harvesting stem cells from the person's own bone marrow or blood followed by chemotherapy and antibody treatment.

25 Sep 2023

New oral agent shows promise in treatment of relapsed multiple myeloma

A new agent that subverts myeloma cells from within while also subjecting them to an immune system attack produced impressive responses in combination with dexamethasone in patients with multiple myeloma that had relapsed and stopped responding to all currently available therapies, a clinical trial conducted by researchers at Dana-Farber Cancer Institute and around the world has found.

30 Aug 2023

Metagenomic next-generation sequencing as an emerging modality for the diagnosis of infectious diseases

Study examined the role of plasma metagenomic next-generation sequencing.

1 Aug 2023

Can a low-bacterial diet improve outcomes for neutropenic cancer patients?

Scientists have reviewed the existing literature to provide evidence of the effectiveness of the low-bacterial diet in neutropenic cancer patients.

20 Jul 2023

What effect does honey have on human health?

Researchers reviewed existing data on the beneficial impact of honey consumption on human health.

12 Jul 2023

Letermovir: A promising breakthrough in CMV prevention for kidney transplant recipients

In a recent article published in the journal JAMA Network, researchers performed a randomized clinical trial (RCT) to demonstrate the noninferiority of letermovir vs. valganciclovir for prophylaxis of cytomegalovirus (CMV) in adult CMV-seronegative kidney transplant recipients (KTRs) who received a kidney from a CMV-seropositive individual.

13 Jun 2023

Patients with high-risk chronic lymphocytic leukemia may benefit from treatment with ibrutinib plus venetoclax

First-line ibrutinib (Imbruvica) plus venetoclax (Venclexta) led to high response and survival rates in patients with chronic lymphocytic leukemia (CLL) whether or not their cancer harbored high-risk genetic features typically associated with poor outcomes, according to results published in Clinical Cancer Research, a journal of the American Association for Cancer Research (AACR).

7 Jun 2023

Study shows efficacy and safety of novel FolRα-targeting antibody drug conjugate in recurrent epithelial ovarian cancer

Updated dose expansion data of the phase I STRO-002-GM1 study have been presented today by Ana Oaknin, Principal Investigator of the Vall d'Hebron Institute of Oncology's (VHIO) Gynecological Malignancies Group, on the ground at the 2023 Annual Meeting of the American Society of Clinical Oncology (ASCO), 2-6 June in Chicago, USA.

4 Jun 2023

The association between breastfeeding, drug exposure, and infant outcomes: more research is needed

Researchers explored the data linking breastfeeding, infant outcomes, and drug exposure.

28 Apr 2023

Research identifies a possible treatment strategy for rare bone marrow failure syndrome

Bone marrow is the spongy tissue inside bone responsible for making red blood cells, white blood cells and platelets. Bone marrow failure syndromes lead to an increased risk of developing dangerous infections, anemia and an increased risk of blood cancers.

2 Mar 2023

Over 50% of cancer patients report long COVID symptoms after recovering from COVID-19

Tesearchers investigate the persistent symptoms experienced by cancer patients who previously recovered from COVID-19.

13 Feb 2023

Adding veliparib to chemotherapy can extend progression-free survival in patients with “BRCA-like” breast cancer

Results from the SWOG S1416 clinical trial show that adding veliparib to chemotherapy can significantly extend progression-free survival (PFS) times in patients with triple-negative breast cancer (TNBC) that has a "BRCA-like" phenotype.

31 Jan 2023

Chemotherapy in the afternoon proved to be effective for female lymphoma patients

Chemotherapy is a commonly used regimen for cancer treatment, but it is also a double-edged sword. While the drugs are highly effective at killing cancer cells, they are also notorious for killing healthy cells in the body.

27 Jan 2023

Chemotherapy schedule affects treatment outcomes in female DLBCL patients

24 Jan 2023

Novel T cell receptor therapy shows early promise for treating solid tumors

Afamitresgene autoleucel (afami-cel; formerly ADP-A2M4), an adoptive T cell receptor (TCR) therapy targeting the MAGE-A4 cancer antigen, achieved clinically significant results for patients with multiple solid tumor types in a Phase I clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.

9 Jan 2023

Delaying antibiotic treatment does not reduce survival chances in cancer patients with neutropenic fever

In cancer patients with neutropenic fever, delaying antibiotic treatment past 60 minutes from the time of fever detection does not reduce the short-term chance of survival, according to a study in the American Journal of Medical Quality.

30 Dec 2022